Literature DB >> 32038919

Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: an effective but still broken option.

Biagio Ricciuti1, Giuseppe Lamberti2, Fausto Roila1, Giulio Metro1.   

Abstract

Entities:  

Year:  2019        PMID： 32038919      PMCID： PMC6987338          DOI： 10.21037/tlcr.2019.04.15

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  15 in total

1.  Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.

Authors:  Justin F Gainor; Leila Dardaei; Satoshi Yoda; Luc Friboulet; Ignaty Leshchiner; Ryohei Katayama; Ibiayi Dagogo-Jack; Shirish Gadgeel; Katherine Schultz; Manrose Singh; Emily Chin; Melissa Parks; Dana Lee; Richard H DiCecca; Elizabeth Lockerman; Tiffany Huynh; Jennifer Logan; Lauren L Ritterhouse; Long P Le; Ashok Muniappan; Subba Digumarthy; Colleen Channick; Colleen Keyes; Gad Getz; Dora Dias-Santagata; Rebecca S Heist; Jochen Lennerz; Lecia V Sequist; Cyril H Benes; A John Iafrate; Mari Mino-Kenudson; Jeffrey A Engelman; Alice T Shaw
Journal:  Cancer Discov       Date:  2016-07-18       Impact factor: 39.397

2.  How might treatment of ALK-positive non-small cell lung cancer change in the near future?

Authors:  Giulio Metro; Guido Bellezza; Francesco Puma; Rita Chiari
Journal:  Expert Rev Anticancer Ther       Date:  2016-08-25       Impact factor: 4.512

3.  Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.

Authors:  Dong-Wan Kim; Marcello Tiseo; Myung-Ju Ahn; Karen L Reckamp; Karin Holmskov Hansen; Sang-We Kim; Rudolf M Huber; Howard L West; Harry J M Groen; Maximilian J Hochmair; Natasha B Leighl; Scott N Gettinger; Corey J Langer; Luis G Paz-Ares Rodríguez; Egbert F Smit; Edward S Kim; William Reichmann; Frank G Haluska; David Kerstein; D Ross Camidge
Journal:  J Clin Oncol       Date:  2017-05-05       Impact factor: 44.544

4.  Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.

Authors:  Solange Peters; D Ross Camidge; Alice T Shaw; Shirish Gadgeel; Jin S Ahn; Dong-Wan Kim; Sai-Hong I Ou; Maurice Pérol; Rafal Dziadziuszko; Rafael Rosell; Ali Zeaiter; Emmanuel Mitry; Sophie Golding; Bogdana Balas; Johannes Noe; Peter N Morcos; Tony Mok
Journal:  N Engl J Med       Date:  2017-06-06       Impact factor: 91.245

Review 5.  Targeting ALK: Precision Medicine Takes on Drug Resistance.

Authors:  Jessica J Lin; Gregory J Riely; Alice T Shaw
Journal:  Cancer Discov       Date:  2017-01-25       Impact factor: 39.397

6.  The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.

Authors:  Sen Zhang; Rana Anjum; Rachel Squillace; Sara Nadworny; Tianjun Zhou; Jeff Keats; Yaoyu Ning; Scott D Wardwell; David Miller; Youngchul Song; Lindsey Eichinger; Lauren Moran; Wei-Sheng Huang; Shuangying Liu; Dong Zou; Yihan Wang; Qurish Mohemmad; Hyun Gyung Jang; Emily Ye; Narayana Narasimhan; Frank Wang; Juan Miret; Xiaotian Zhu; Tim Clackson; David Dalgarno; William C Shakespeare; Victor M Rivera
Journal:  Clin Cancer Res       Date:  2016-10-25       Impact factor: 12.531

7.  Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations.

Authors:  Ted W Johnson; Paul F Richardson; Simon Bailey; Alexei Brooun; Benjamin J Burke; Michael R Collins; J Jean Cui; Judith G Deal; Ya-Li Deng; Dac Dinh; Lars D Engstrom; Mingying He; Jacqui Hoffman; Robert L Hoffman; Qinhua Huang; Robert S Kania; John C Kath; Hieu Lam; Justine L Lam; Phuong T Le; Laura Lingardo; Wei Liu; Michele McTigue; Cynthia L Palmer; Neal W Sach; Tod Smeal; Graham L Smith; Albert E Stewart; Sergei Timofeevski; Huichun Zhu; Jinjiang Zhu; Helen Y Zou; Martin P Edwards
Journal:  J Med Chem       Date:  2014-06-03       Impact factor: 7.446

8.  Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC.

Authors:  Jessica J Lin; Viola W Zhu; Adam J Schoenfeld; Beow Y Yeap; Ashish Saxena; Lorin A Ferris; Ibiayi Dagogo-Jack; Anna F Farago; Angela Taber; Anne Traynor; Smitha Menon; Justin F Gainor; Jochen K Lennerz; Andrew J Plodkowski; Subba R Digumarthy; Sai-Hong Ignatius Ou; Alice T Shaw; Gregory J Riely
Journal:  J Thorac Oncol       Date:  2018-06-20       Impact factor: 15.609

9.  ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.

Authors:  Alice T Shaw; Benjamin J Solomon; Benjamin Besse; Todd M Bauer; Chia-Chi Lin; Ross A Soo; Gregory J Riely; Sai-Hong Ignatius Ou; Jill S Clancy; Sherry Li; Antonello Abbattista; Holger Thurm; Miyako Satouchi; D Ross Camidge; Steven Kao; Rita Chiari; Shirish M Gadgeel; Enriqueta Felip; Jean-François Martini
Journal:  J Clin Oncol       Date:  2019-03-20       Impact factor: 44.544

Review 10.  Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy.

Authors:  Robert Ali; Junaid Arshad; Sofia Palacio; Raja Mudad
Journal:  Drug Des Devel Ther       Date:  2019-02-08       Impact factor: 4.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.